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Objectives The aim of this study was to describe the characteristics and outcome of all consecutive patients treated with
percutaneous coronary intervention (PCI) in an unselected nationwide cohort over the past 2 decades.
Background Over the last 20 years, treatment with PCI has evolved dramatically, but the change in patient characteristics
has not been well described.
Methods We included all patients undergoing a PCI procedure for the first time between January 1990 and December
2010 from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). Patients were divided into
different cohorts on the basis of the year of the first PCI procedure.
Results A total of 144,039 patients was included. The mean age increased from 60.1  9.9 years in 1990 to 1995
to 67.1  11.2 years in 2009 to 2010. The proportion of patients presenting with unstable coronary artery
disease and ST-segment elevation myocardial infarction increased from 27.4% and 6.2% to 47.7% and
32.5%, respectively. Diabetes mellitus and multivessel disease were more often present in the later-year
cohorts. The 1-year mortality increased from 2.2% in 1990 to 1995 to 5.9% in 2009 to 2010, but after ad-
justment for age and indication, a modest decrease was shown, mainly in ST-segment elevation myocardial
infarction patients.
Conclusions Characteristics of PCI patients have changed substantially over time, reflecting the establishment of new evi-
dence. The increasing age and proportion of patients undergoing PCI for acute coronary syndromes greatly influ-
ence outcome. Understanding the changing patient characteristics is important for the translation of evidence to
real-world clinical practice. (J Am Coll Cardiol 2013;61:1222–30) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.007Percutaneous coronary intervention (PCI) is often part of
standard therapy in patients presenting with significant
coronary artery disease (1). Since the introduction of
CI, the procedure itself has evolved dramatically, with
he introduction of bare-metal stents (BMS) and subse-
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The Swedish Coronary Angiography and Angioplasty Registry SCAAR isquently drug-eluting stents (DES) (2– 4). In addition,
primary PCI is now the recommended treatment in
patients with ST-segment elevation myocardial infarc-
tion (STEMI), and it has resulted in a mortality reduc-
tion (5,6). Furthermore, PCI is increasingly used in
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disease (7).
However, the risk profile of patients undergoing a PCI
rocedure has also changed substantially over time. Today,
CI is increasingly recommended for elderly patients with
cute coronary syndromes, although they are often excluded
rom randomized trials (8). The changing patient charac-
eristics may greatly influence outcome after PCI in ran-
omized trials as well as in registry studies. It is, therefore,
mportant to understand the changes in real-world clinical
ractice. After 20 years of PCI procedures, we found it
pportune to present the clinical characteristics and out-
ome of all consecutive patients treated with PCI in an
nselected nationwide cohort.
ethods
tudy population. In this descriptive study, we included
ll patients in Sweden undergoing their first PCI proce-
ure between January 1990 and December 2010. All
epeat procedures were excluded, to use the information
rom each patient only once. A PCI procedure was
efined as any use of a guidewire for more than only
iagnostic purposes. Patients without a Swedish personal
dentification number and patients with a missing proce-
ure type were excluded.
CAAR data. The SCAAR (Swedish Coronary Angiog-
aphy and Angioplasty Registry), which is a part of the
WEDEHEART registry, documents all consecutive cor-
nary angiographies and PCI procedures performed in
weden (9,10). All 30 hospitals with a catheterization
aboratory enroll all patients. During the first years, a few
CI procedures may have been performed outside of the
CAAR registry. The data are collected prospectively,
ccording to data registration standards for clinical practice,
nd are audited and monitored as previously described
11,12). Data about medical history were obtained from the
ational Patient Register. In this register, the discharge
iagnoses are collected of all hospitalizations in Sweden on
he basis of the International Classification of Diseases
ICD), from 1987 and forward (13). The vital status and
ate of death were obtained from the Swedish National
opulation Registry until December 31, 2011; hence, all
atients have at least 1-year of follow-up. Data from these
ational registers were merged with SCAAR on the basis of
he personal identification number that all Swedish citizens
ave. The merging was performed by the Epidemiologic
enter of the Swedish National Board of Health and
elfare, and was approved by the ethics committee of
ppsala University.
The indication for PCI was categorized as stable coronary
rtery disease, unstable coronary artery disease (non-
TEMI with or without elevation of biomarkers of cardiac
schemia), STEMI, and other (e.g., cardiac arrest, heart
ailure, and arrhythmia). The definitions of the different
ndications have not changed over time. In SCAAR, smoking owas defined as smoking in the 30
days before the PCI procedure.
The risk factors diabetes mellitus,
hyperlipidemia, and hypertension
were defined by the medical treat-
ment for the condition at the time
of the PCI procedure. For diabe-
tes, patient history and hospital
records were also evaluated to in-
clude patients with diabetes on a
dietary treatment.
Statistical analysis. The pa-
tients were divided into 8 differ-
ent cohorts on the basis of the
year of the first PCI procedure.
New registry variables and ther-
apies were introduced during the
study period and, therefore, data
are partly or completely missing
in some year cohorts. Categorical variables are presented as
frequency values and proportions. Continuous variables
with a normal distribution are presented as mean SD. We
have chosen not to present p values for the patient charac-
teristics because this study does not include a sample, but
rather the total population. The cumulative incidence of
mortality was presented by Kaplan-Meier event curves for
the different year cohorts. Cox regression analyses were
performed to adjust for covariates. We adjusted only for age
and indication, as not all baseline variables were available in
all year cohorts. The adjusted hazard ratio (HR) is reported
together with the corresponding 95% confidence interval
(CI). The log minus log test and the scaled Schoenfeld
residuals were performed to test the proportional hazard
assumption of the covariates. In addition, sex-specific out-
come was evaluated, and we also performed the analyses for
all PCI procedures, included repeated PCI procedures. For
the survival analyses, 2-sided p values 0.05 were defined as
ignificant. Statistical analyses were performed using SPSS
ersion 20.0 (SPSS, IBM Corporation, Armonk, New
ork).
esults
total of 450,859 procedures were performed in 317,444
atients admitted to any catheterization laboratory in
weden between January 1990 and December 2010 (Fig. 1).
total of 144,039 patients undergoing a PCI for the first
ime (72.5%) were analyzed. In SCAAR, the annual inci-
ence of first-time PCI increased to 13,189 patients in 2006
nd remained relatively stable thereafter. The number of
ospitals performing PCI procedures increased from 9
etween 1990 to 1995 to 29 in 2007 and onwards (Table 1).
vailable data. Age and sex were available for all included
atients, and the indication for PCI was available for 99.5%
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CI  confidence interval
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
HR  hazard ratio
ICD  International
Classification of Diseases
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionf the patients. Diabetes, hypertension, hyperlipidemia, and
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Population Trends in Percutaneous Intervention March 26, 2013:1222–30smoking were not registered before 1995. From 1995 to
1998, 80% of these data were missing. However, risk factor
data increased over time, and there were no missing data
after 2005. The angiographic findings were available in 52%
of the patients between 1996 and 2002. From 2003, 99.5%
of the angiographic data were available. Data regarding
Figure 1 Flow Chart
Flow chart of the percutaneous coronary intervention (PCI) patients included in the
Baseline CharacteristicsTable 1 Baseline Characteristics
Variable
1990–1995
(n  10,200)
1996–1998
(n  9,825)
1999–2000
(n  11,121)
200
(n 
Number of hospitals 9 11 14
Mean age, yrs 60.1 9.9 61.9 10.4 63.1 10.8 64.
75 yrs 592 (5.8%) 1,172 (11.9%) 1,773 (15.9%) 3,01
Male 7,489 (73.4%) 7,150 (72.8%) 7,942 (71.4%) 11,18
Indication
Stable CAD 6,583 (66.4%) 5,125 (53.2%) 4,179 (37.6%) 4,91
Unstable CAD 2,715 (27.4%) 3,584 (37.2%) 5,223 (47.0%) 7,40
STEMI 611 (6.2%) 883 (9.2%) 1,569 (14.1%) 2,67
Other 10 (0.1%) 43 (0.4%) 150 (1.3%) 73
Current smoker 459 (19.7%) 2,279 (20.5%) 3,29
Diabetes mellitus 314 (13.4%) 1,744 (15.7%) 2,53
Hyperlipidemia 1,088 (61.2%) 5,079 (49.0%) 6,64
Hypertension 802 (34.4%) 3,994 (36.0%) 5,25
History of
Myocardial
infarction
3,623 (35.5%) 3,337 (34.0%) 3,319 (29.8%) 3,97
CABG 624 (6.1%) 770 (7.8%) 890 (8.0%) 1,21
Heart failure 557 (5.5%) 705 (7.2%) 785 (7.1%) 1,09
Stroke 368 (3.6%) 527 (5.4%) 609 (5.5%) 89
Renal failure 44 (0.4%) 88 (0.9%) 114 (1.0%) 16Values are mean  SD or n (%).
CABG  coronary artery bypass grafting; CAD  coronary artery disease; STEMI  ST-segment elevatiotype of stent (BMS or DES) were available for 86% of
stented patients during 2002, and for all patients afterwards.
In addition, stent length and diameter were available for
60% until 2002, and for 100% afterward. For medication,
data were complete in 99.8% of the patients after the
introduction of each variable.
sis.
02
38)
2003–2004
(n  20,801)
2005–2006
(n  25,679)
2007–2008
(n  25,532)
2009–2010
(n  25,143)
26 27 29 29
.8 65.3 10.9 66.6 11.0 66.7 11.2 67.1 11.2
.2%) 4,716 (22.7%) 6,887 (26.8%) 7,011 (27.5%) 7,131 (28.4%)
.1%) 14,882 (71.5%) 18,311 (71.3%) 18,054 (70.7%) 17,986 (71.5%)
.3%) 4,944 (24.0%) 5,185 (20.2%) 4,425 (17.3%) 4,240 (16.9%)
.1%) 10,656 (51.7%) 12,521 (48.8%) 12,174 (47.7%) 12,000 (47.7%)
.0%) 4,818 (23.4%) 7,569 (29.5%) 8,402 (32.9%) 8,180 (32.5%)
%) 202 (1.0%) 404 (1.6%) 531 (2.1%) 723 (2.9%)
.6%) 4,473 (21.5%) 5,433 (21.2%) 5,533 (21.7%) 5,474 (21.8%)
.6%) 3,396 (16.4%) 4,492 (17.5%) 4,310 (16.9%) 4,397 (17.5%)
.4%) 9,898 (48.5%) 11,491 (44.7%) 10,348 (40.5%) 9,997 (39.8%)
.4%) 9,078 (43.7%) 11,985 (46.7%) 12,414 (48.6%) 12,919 (51.4%)
.2%) 3,882 (18.7%) 3,576 (13.9%) 2,799 (11.0%) 2,483 (9.9%)
%) 1,483 (7.1%) 1,682 (6.6%) 1,684 (6.6%) 1,572 (6.3%)
%) 1,323 (6.4%) 1,615 (6.3%) 1,388 (5.4%) 1,380 (5.5%)
%) 1,214 (5.8%) 1,668 (6.5%) 1,577 (6.2%) 1,542 (6.1%)
%) 226 (1.1%) 367 (1.4%) 380 (1.5%) 447 (1.8%)analy1–20
15,7
22
1 10
9 (19
9 (71
7 (31
3 (47
5 (17
5 (4.7
2 (21
0 (16
4 (46
0 (34
2 (25
5 (7.7
1 (6.9
9 (5.7
6 (1.1n myocardial infarction.
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the PCI patients increased over the year cohorts, from a
mean age of 60.19.9 years in the cohort 1990 to 1995, to
67.111.2 years in the cohort 2009 to 2010 (Table 1). The
proportion of patients ages 75 years increased from 5.8%
to 28.4%. The indication for PCI changed over time, with
a majority of patients treated for stable coronary artery
disease (66.4%) in 1990 to 1995, and a majority treated for
unstable coronary artery disease (47.7%) or STEMI (32.5%)
in 2009 to 2010 (Fig. 2). The proportion of smokers was
between 19.7% and 21.8% in the different year cohorts.
Diabetes and hypertension increased while hyperlipidemia
decreased, and a lower proportion of patients had a history
of myocardial infarction over time. Three-vessel disease
increased from 3.8% in the cohort 1990 to 1995, to 17.3%
to 19.0% in the cohorts from 2003 to 2010 (Table 2). In
addition, stent use increased from nearly no stent usage
(0.8%) to approximately 93% from the cohort 2003 to 2004
and later. Among the patients treated with a stent, the
proportion receiving DES varied between 17.2% and 48.0%
after its introduction in 2002.
Mortality. Figure 3A shows the mortality for the different
year cohorts, with a median follow-up of 2,082 days
(interquartile range: 1,105 to 3,335 days), and up to 21 years
of total follow-up. The mortality rate was higher in the later
year cohorts compared to the earlier year cohorts. Mortality
at 1 year after PCI increased from 2.2% in 1990 to 1995, to
5.9% in 2009 to 2010 (Table 3). After adjustment for age
Figure 2 Indication for PCI Procedure
Proportion of patients undergoing percutaneous coronary intervention (PCI) for sta
unstable CAD (green bars), ST-segment elevation myocardial infarction (STEMI) (reand indication, a modest decrease in the mortality risk was
seen over time (Fig. 3B). That was mainly due to a decrease
in the risk of mortality in the subgroup of STEMI patients,
with an age-adjusted HR up to approximately 2 in the
earlier year cohorts, compared to the reference cohort 2009
to 2010 (Table 3, Fig. 4). Furthermore, the unadjusted
mortality rate was lower in males compared to females in the
long term after PCI (HR: 0.82 [95% CI: 0.80 to 0.84]).
However, after adjustment for age, indication, and year
cohort, no sex difference was seen at 1 year after PCI (HR:
1.00 [95% CI: 0.95 to 1.06]), whereas males had a slightly
higher risk of mortality in the long term (HR: 1.12 [95%
CI: 1.09 to 1.15]). When we performed the analyses in all
PCI procedures, including repeated PCI procedures, the
results were consistent.
Discussion
We evaluated the clinical characteristics of all consecutive
patients undergoing a first PCI procedure in Sweden in the
last 2 decades. The mean age of the PCI treated population
increased, and patients were more often treated for unstable
coronary artery disease or STEMI over time. As a conse-
quence of the older population, the proportion of patients
with comorbidities increased. Mortality after PCI was
influenced by the increasing age and the changing indica-
tion for PCI.
onary artery disease (CAD) (blue bars),
s), and other (lavender bars) in the different year cohorts.ble cor
d bar
Angiographic and Procedural CharacteristicsTable 2 Angiographic and Procedural Characteristics
Variable
1990–1995
(n  10,200)
1996–1998
(n  9,825)
1999–2000
(n  11,121)
2001–2002
(n  15,738)
2003–2004
(n  20,801)
2005–2006
(n  25,679)
2007–2008
(n  25,532)
2009–2010
(n  25,143)
Angiographic findings
1-vessel disease 7,266 (73.1%) 5,282 (71.0%) 1,772 (49.3%) 3,975 (48.7%) 9,544 (47.5%) 11,660 (45.9%) 12,222 (48.0%) 11,689 (46.5%)
2-vessel disease 2,082 (20.9%) 1,617 (21.7%) 1,138 (31.7%) 2,546 (31.2%) 6,095 (30.3%) 7,648 (30.1%) 7,390 (29.0%) 7,246 (28.8%)
3-vessel disease 376 (3.8%) 382 (5.1%) 547 (15.2%) 1,380 (16.9%) 3,570 (17.8%) 4,817 (19.0%) 4,462 (17.5%) 4,344 (17.3%)
Left main CAD 58 (0.6%) 114 (1.5%) 96 (2.7%) 207 (2.5%) 809 (4.0%) 1,156 (4.6%) 1,147 (4.5%) 1,232 (4.9%)
Stent use 80 (0.8%) 1,541 (15.7%) 9,552 (85.9%) 14,064 (89.4%) 19,339 (93.0%) 23,962 (93.3%) 23,681 (92.8%) 23,335 (92.8%)
Drug-eluting stent 111 (1.0%) 5,608 (29.1%) 11,500 (48.0%) 4,083 (17.2%) 7,476 (32.0%)
Number of stents
1 943 (9.6%) 4,328 (38.9%) 7,708 (49.0%) 11,740 (56.4%) 12,773 (49.7%) 13,084 (51.2%) 12,747 (50.7%)
2 100 (1.0%) 1,179 (10.6%) 2,738 (17.4%) 5,311 (25.5%) 7,910 (30.8%) 7,904 (31.0%) 7,780 (30.9%)
3 3 (0.0%) 313 (2.8%) 1,117 (7.1%) 2,233 (10.7%) 3,278 (12.8%) 2,693 (10.5%) 2,825 (11.2%)
Stent size, mm
Stent length 20.53 8.47 18.98 11.01 21.42 13.23 25.80 15.84 29.06 17.83§ 27.53 16.27 29.09 17.41
Stent diameter 3.00 0.39 3.05 0.43 3.09 0.44 3.05 0.46 3.01 0.48 3.06 0.49 3.05 0.51
General success rate 8,207 (90.3%) 8,489 (93.1%) 10,413 (98.5%) 13,926 (97.2%) 19,417 (95.1%) 24,168 (94.1%) 24,036 (94.1%) 23,682 (94.2%)
Medication
Aspirin before PCI 17,593 (84.6%) 23,407 (91.2%) 23,238 (91.0%) 23,131 (92.0%)
Aspirin during PCI 1,803 (8.7%) 1,731 (6.8%) 1,745 (6.8%) 1,451 (5.8%)
P2Y12 inhibitor before PCI 11,213 (54.0%) 18,520 (72.2%) 20,791 (81.4%) 21,157 (84.2%)
P2Y12 inhibitor during PCI 5,660 (27.3%) 5,598 (22.0%) 3,909 (15.3%) 3,459 (13.8%)
GPIIb/IIIa inhibitor before PCI 1,117 (5.4%) 1,635 (6.4%) 1,003 (3.9%) 436 (1.7%)
GPIIb/IIIa inhibitor during PCI 7,344 (35.4%) 8,806 (34.5%) 7,553 (29.6%) 4,616 (18.4%)
Bivalirudin before PCI 22 (0.1%) 63 (0.2%) 118 (0.5%)
Bivalirudin during PCI 2,163 (10.0%) 4,718 (18.5%) 7,005 (27.9%)
Acute CABG after PCI 121 (1.2%) 49 (0.5%) 32 (0.3%) 16 (0.1%) 22 (0.1%) 29 (0.1%) 16 (0.1%) 11 (0.0%)
Values are n (%) or mean SD.
GP  glycoprotein; PCI  percutaneous coronary intervention; other abbreviations as in Table 1.
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March 26, 2013:1222–30 Population Trends in Percutaneous InterventionThis study gives an overview of a nationwide population
including virtually all patients undergoing a PCI procedure
for the first time in all PCI centers in Sweden. To be able
to interpret the results of clinical trials and registries, it is
important to understand how the PCI population has
changed over time. Changing characteristics of PCI patients
Figure 3 Total Mortality in the Different Year Cohorts
(A) Cumulative incidence of death in the different year cohorts. (B) Adjusted
survival curve for the risk of death in the different year cohorts, adjusted for
age and indication.have been previously described by Singh et al. (14) in a largeM
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Population Trends in Percutaneous Intervention March 26, 2013:1222–30cohort over 25 years, but did only include patients from a
single institution.
The mean age of the PCI patients increased by 7 years
over the 20-year study period. Patients ages 75 years
currently represent 28% of the whole PCI population. As
mortality rates have been reduced in elderly thanks to
evidence-based treatment for acute coronary syndromes
(15), guidelines nowadays recommend an invasive strat-
egy for this high-risk subgroup (8). In addition, we
Figure 4 Mortality During the First Year for Every Indication, A
Age-adjusted survival curve for the risk of death in the different year cohorts d
2000 (tan line); 2001 to 2002 (purple line); 2003 to 2004 (yellow line); 200
line). (A) Stable coronary artery disease; (B) unstable coronary artery disease
intervention.observed a change in the indication of PCI over time,with an increase in the proportion of patients undergoing
a PCI procedure for acute coronary syndromes. This
change was mainly caused by an increase in the total
number of patients with unstable coronary artery disease
and STEMI undergoing PCI. In patients with STEMI,
primary PCI is the recommended therapy, and it has been
implemented over the years (5,6,16). In addition, it has
also been shown that patients with non-STEMI acute
coronary syndromes benefit from an early invasive strat-
ed
he first year: 1990 to 1995 (blue line); 1996 to 1998 (green line); 1999 to
006 (red line); 2007 to 2008 (turquoise line); and 2009 to 2010 (black
T-segment elevation myocardial infarction. PCI  percutaneous coronarydjust
uring t
5 to 2
; (C) Segy compared to a conservative therapy (17).
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March 26, 2013:1222–30 Population Trends in Percutaneous InterventionStent use increased substantially to a proportion of
approximately 93%, which was consistent with other
contemporary studies (18). The proportion of patients
receiving DES increased rapidly until 2006, followed by
a sharp decline. The uncertainty about the risk of late
stent thrombosis in patients receiving DES compared to
BMS and a recommendation of a restricted use of DES
by the Swedish health authorities greatly influenced this
(19). The documented reduction in the incidence of
restenosis, especially in specific subgroups such as small
stent diameter, long stents, and patients with diabetes,
contributed to a new increase in the use of DES from
2008 (4).
Many efforts have been made to improve clinical
outcomes in patients with significant coronary artery
disease. In our study, unadjusted data showed that the
mortality increased over the year cohorts. After adjust-
ment for the increasing age and the changing indication,
the mortality risk decreased over time. This finding
greatly illustrates the influence of the changing PCI
population on outcome. In the subgroup of STEMI
patients, we observed a lower mortality in the consecutive
year cohorts. Nevertheless, it is important to emphasize
the changing selection of STEMI patients undergoing a
PCI procedure, as STEMI patients received fibrinolysis
as the primary reperfusion therapy in the earlier years. In
addition, pre-treatment with antithrombotic and anti-
platelet therapies may have contributed to a decrease in
mortality over time.
Study limitations. As in all observational studies of
registry data, there are several limitations that need to be
addressed. Data from observational registries typically
have lower quality, and there are more missing data as
compared to randomized clinical trials. Because of miss-
ing data in the first year cohorts, we did not adjust for all
potential confounders in the Cox regression analysis for
mortality. In addition, although the definitions of the
different indications of PCI did not change over time, the
interpretation of the definitions may have changed
slightly.
Conclusions
As shown by our nationwide, all-comers study, the patient
population undergoing PCI has substantially changed over
the last 20 years, reflecting the establishment of new
evidence into clinical practice. Despite a population with an
increasing risk, the adjusted mortality modestly decreased in
the overall PCI population over the different year cohorts.
However, only in the subgroup of STEMI patients was a
clinically relevant reduction in mortality seen over time,
suggesting that the treatment for this indication continu-
ously improves. The understanding of changing patient
characteristics and baseline risk factors is important for the
translation of evidence to real-world clinical practice. The
changing patient population should be taken into account inthe interpretation of previous studies and the design of
future trials.
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